Clinical Trial Update: Phase I Study of Safety and Persistence of UC-781 Vaginal Microbicide [Phase 1]

View source ↗

Summary

Phase I study evaluating the safety and persistence of the UC-781 vaginal microbicide for HIV prevention has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• UC-781

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED